VANCOMYCIN Drug Patent Profile

Which patents cover Vancomycin, and when can generic versions of Vancomycin launch?

Vancomycin is a drug marketed by Hikma, Fresenius Kabi Usa, Lupin, Orient Pharma Co Ltd, Pai Holdings, Strides Pharma, Watson Labs, Alkem Labs Ltd, Amneal, Aspiro, Avet Lifesciences, Eugia Pharma, Eurofarma, Gland, Hikma Pharms, Hospira, Hospira Inc, Knack, Meitheal, Mylan Labs Ltd, Plano Pharms, Sagent Pharms, Slate Run Pharma, Teva Pharms Usa, Xellia Pharms Aps, Samson Medcl, Steriscience, Zhejiang Novus Pharm, and Baxter Hlthcare. and is included in fifty-five NDAs. There are five patents protecting this drug.

This drug has forty-nine patent family members in twenty-nine countries.

The generic ingredient in VANCOMYCIN is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vancomycin

A generic version of VANCOMYCIN was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17^th, 1987.

Summary for VANCOMYCIN

International Patents:	49
US Patents:	5
Applicants:	29
NDAs:	55
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	481
Drug Prices:	Drug price information for VANCOMYCIN
What excipients (inactive ingredients) are in VANCOMYCIN?	VANCOMYCIN excipients list
DailyMed Link:	VANCOMYCIN at DailyMed

See drug prices for VANCOMYCIN

See drug sales revenues for VANCOMYCIN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VANCOMYCIN

NDA:

213895

Dosage:

SOLUTION;INTRAVENOUS, ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VANCOMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE3
The Methodist Hospital Research Institute	NA
Nantes University Hospital	PHASE2

See all VANCOMYCIN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for VANCOMYCIN

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

J01XA	Glycopeptide antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for VANCOMYCIN

VANCOMYCIN is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	091554-001	Sep 19, 2011	AP	RX	No	Yes
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	POWDER;INTRAVENOUS	209481-003	Jul 10, 2018	AP	RX	Yes	Yes
Gland	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	205694-001	Jan 21, 2016	AP	RX	No	No
Eurofarma	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	065401-001	Jun 30, 2008	AP	RX	No	No

International Patents for VANCOMYCIN

When does loss-of-exclusivity occur for VANCOMYCIN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Mexico

New Zealand

Philippines

Poland

Portugal

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VANCOMYCIN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015341763
Brazil	112017009405
Canada	2964524
Chile	2017001139

Vancomycin: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

How big is the vancomycin market and how is it moving?

Vancomycin is a mature, off-patent antibiotic with persistent demand driven by hospital infection control needs, rising antimicrobial resistance pressure, and ongoing treatment of serious Gram-positive infections. Commercially, the market tracks the hospital environment more than new-product innovation cycles.

Demand anchors

• Hospital and long-term care consumption: Vancomycin use is concentrated in inpatient settings (ICU, surgery, oncology, transplant units) and in institutions managing high-risk patients.
• Resistance and stewardship: MRSA prevalence and hospital infection control programs keep baseline utilization steady, while stewardship policies shape dosing and duration.
• Core clinical positioning: Vancomycin remains a standard-of-care option for serious suspected or confirmed Gram-positive infections where empiric coverage or MRSA risk exists.

Competitive structure

• Multiple authorized generic manufacturers: Pricing power is limited, and the market typically clears at competitive generic levels.
• Biosafety and supply stability considerations: Contract manufacturing capacity and sterile injectables supply can affect short-term availability and pricing.

What market forces are shaping pricing and share?

1) Generic erosion and tender-driven pricing

The largest determinant of financial trajectory for vancomycin is channel pricing in hospitals through:

• Group purchasing organization (GPO) contracts
• Institutional tenders
• Automatic substitution and formulary preference rules for injectables

As more competitors participate and hospitals lock in multi-quarter procurement contracts, net price usually compresses unless supply constraints or regulatory actions intervene.

2) Formulation mix: vial size, concentration, and therapeutic substitution

Vancomycin’s financial profile depends on:

• Injection presentations (single-dose vials, vial strengths)
• Hospital pharmacy handling preferences
• Substitution by alternative agents when local antimicrobial guidelines shift (for example, when linezolid or daptomycin is preferred in specific scenarios)

3) Safety and dosing governance

Clinical governance can influence volume and duration:

• Protocol-driven dosing, therapeutic drug monitoring, and renal dosing adjustments can affect utilization patterns.
• Shifts in stewardship targets may reduce unnecessary courses but still preserve demand for severe infections.

4) Regulatory and manufacturing continuity

Vancomycin’s mature status means financial outcomes are sensitive to supply disruptions:

• Sterile injectable manufacturing interruptions can spike pricing temporarily.
• Regulatory issues affecting specific sites or product lots can change effective supply and raise short-term procurement costs.

How does product lifecycle affect vancomycin’s financial trajectory?

Vancomycin’s lifecycle is defined by:

• Low brand premium (limited patent-driven pricing)
• High-volume, low-margin procurement economics
• Continuous competitive replenishment by generics

This creates a financial trajectory pattern common to off-patent sterile injectables:

• Revenue tends to track volume (infection burden and hospital admissions)
• Profit pools shift to efficient manufacturing and contracting rather than differentiation
• Price compression dominates topline growth, unless volume expands faster than pricing declines

What are the key revenue and cost drivers?

Revenue drivers

• US and EU hospital discharge and ICU occupancy levels
• MRSA case mix and empiric therapy practices
• Infection control initiatives that increase antibiotic use for suspected bacterial infections
• Formulary status and contract renewals

Cost drivers

• Sterile manufacturing overhead (cleanroom, aseptic process controls, QC release)
• Raw materials and utility costs
• Quality systems and batch testing
• Regulatory compliance costs (inspection readiness)
• Working capital and logistics for cold-chain-adjacent storage requirements (where applicable)

How do financial outcomes typically vary by geography and channel?

US

• Large generic competitive set and strong contracting dynamics.
• Hospital formulary practices and PBM/GPO structures drive net pricing.
• Demand is stable with modest cyclical influence from admission rates.

Europe

• More frequent price regulation and tender-based procurement can create tighter net-price ranges.
• Uptake depends on reimbursement mechanisms and national hospital formularies.

Developing markets

• Lower price ceilings and procurement irregularities can create volume volatility.
• Supply chain quality and distributor networks materially affect continuity.

What is the competitive and substitution landscape?

Direct competitive alternatives

Vancomycin is routinely compared against other Gram-positive agents depending on:

• severity and site of infection (skin/soft tissue, bacteremia, pneumonia)
• MRSA risk
• renal impairment
• treatment monitoring capability

Common comparators in hospital protocols include linezolid, daptomycin, telavancin (market access dependent), and other beta-lactams for MRSA where appropriate.

Substitution pressure

Substitution does not eliminate demand for vancomycin because:

• many guidelines still include vancomycin for initial empiric coverage in severe infection
• stewardship practices often retain vancomycin as a fallback or confirmatory therapy

The net effect is that vancomycin typically faces share volatility at the margins, but it retains baseline volume.

What financial trajectory indicators matter for stakeholders?

For investors, commercial planners, and R&D portfolio owners, the following indicators typically drive valuation and planning for vancomycin-like sterile injectables:

Indicator	What it signals	Typical direction for mature products
Net price vs list	Tender and GPO outcomes	Downward or flat over time
Volume (doses)	Infection burden and hospital use	Stable to modest growth
Contract renewal timing	Procurement cycle impacts	Quarter-to-quarter volatility
Supply continuity	Plant uptime and lot release	Can swing revenue profitability
Compliance events	FDA/EMA warning letters, recalls	Short-term disruption, longer-term margin pressure

How does vancomycin’s market compare to newer Gram-positive antibiotics?

Newer agents usually command premium pricing when patents or exclusivity exist. Vancomycin instead behaves like a “base layer” antibiotic:

• Lower pricing but persistent absolute demand
• Less product differentiation
• Higher sensitivity to procurement economics and supply continuity

This means vancomycin’s financial trajectory is more correlated with hospital purchasing and supply logistics than with science breakthroughs.

What does the regulatory and brand history imply for long-term economics?

Vancomycin has longstanding clinical use and broad availability. In mature antibiotics:

• Patent expiry and generic entry compress prices structurally
• Long-term growth relies on volume expansion and manufacturer execution rather than innovation-driven premiumization

That structure tends to stabilize demand but caps margins.

Key commercial scenario outcomes

Base case

• Competitive pressure holds net prices steady-to-down
• Volume stays stable with healthcare utilization
• Profitability depends on manufacturing efficiency and contract position

Upside

• Supply constraints or lot availability issues temporarily strengthen pricing
• Infection burden rises and empiric use increases
• Contracting dynamics favor higher-volume producers

Downside

• Price cuts intensify due to additional generic competition
• Shift toward alternative agents reduces share in specific indications
• Compliance or manufacturing disruptions cause loss of tender participation

What is the practical financial trajectory for vancomycin manufacturers?

For stakeholders owning manufacturing or distribution rights in off-patent vancomycin, the financial trajectory typically looks like:

• Revenue: stable to slowly declining per unit price; total revenue driven by dose throughput and contract win rates
• Gross margin: under sustained pressure; episodic improvement when supply tightness or fewer available competitors align
• Operating margin: sensitive to QC costs, batch failures, and regulatory risk events

This is consistent with sterile injectable generics where the major differentiator is reliability of supply at the contracted cost, not product novelty.

What should investors and strategists monitor next?

• Tender calendar and contract renewals in major hospital systems
• Site-level manufacturing performance (lot release rates and inspection outcomes)
• Net pricing trend versus list and versus primary generic competitors
• Therapeutic guideline updates that shift empiric coverage recommendations
• MRSA epidemiology changes impacting empiric dosing decisions

---

Key Takeaways

• Vancomycin is a mature, off-patent hospital antibiotic whose market is driven primarily by hospital infection patterns and procurement contracting, not by innovation cycles.
• Net pricing compresses structurally under generic competition; financial performance depends on volume execution and supply continuity.
• Revenue tends to track dosing demand in inpatient settings, while margins hinge on aseptic manufacturing efficiency, QC reliability, and regulatory outcomes.
• Competitive pressure from newer Gram-positive agents typically creates marginal share volatility rather than market elimination.

---

FAQs

1. Why does vancomycin demand remain resilient despite generic erosion?
   Because inpatient protocols retain vancomycin for serious Gram-positive infections, particularly when MRSA risk is present, and usage is concentrated in hospitals with persistent high-acuity care.

2. What has the biggest impact on vancomycin net price in the US?
   GPO and hospital tender contracting dynamics, which often set net price below list and drive ongoing erosion among competing suppliers.

3. Do alternative antibiotics materially reduce vancomycin volume?
   They can shift share in specific indications or patient profiles, but vancomycin generally maintains baseline demand because it remains in empiric and confirmatory pathways for severe infections.

4. What operational factors most influence profitability for vancomycin manufacturers?
   Aseptic manufacturing yield, lot release throughput, QC costs, and inspection outcomes that affect the ability to supply contracted demand.

5. How sensitive is vancomycin to supply disruptions?
   High. Sterile injectable shortages can quickly change effective supply and alter short-term pricing and contract allocations.

---

References

[1] FDA. (n.d.). Vancomycin hydrochloride injection drug safety and labeling resources. U.S. Food and Drug Administration. https://www.fda.gov/
[2] EMA. (n.d.). Vancomycin information and product documentation. European Medicines Agency. https://www.ema.europa.eu/
[3] IDSA. (n.d.). Guidelines on the treatment of MRSA and other Gram-positive infections. Infectious Diseases Society of America. https://www.idsociety.org/

DrugChatter Q&A for VANCOMYCIN

Vancomycin antibiotic price?
Vancomycin hydrochloride in plastic container discount?
Why is vancomycin so expensive?
Vancomycin trade and generic name?
Vancomycin hydrochloride price trend?